The purpose of this study is to determine if the combination of once-daily tacrolimus
extended-release (EnvarsusXR) and Azathioprine is non inferior with respect to the composite
outcome of acute rejection, graft and patient survival as compared to a combination of
twice-daily immediate release tacrolimus and mycophenolate mofetil/mycophenolic acid.